A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

• Status: Completed
• Trial end date: 2010-05-01

Summary

The purpose of this study is to investigate how efficient TMC435350 will work against the Hepatitis C virus genotype 1 (genotypes refer to the genetic constitution of the virus) and what the concentrations of TMC435350 in the blood are with or without pegylated interferon alpha-2a (PegIFNa-2a) or PegIFNa-2a plus ribavirin.

• Phase: Phase 2

Details

• Lead Sponsor: Tibotec Pharmaceuticals, Ireland
• Treatments: Interferon-alpha; Peginterferon alfa-2a; Ribavirin; Simeprevir